HRP20230342T1 - Kationski lipid koji se može ionizirati za isporuku rna - Google Patents

Kationski lipid koji se može ionizirati za isporuku rna Download PDF

Info

Publication number
HRP20230342T1
HRP20230342T1 HRP20230342TT HRP20230342T HRP20230342T1 HR P20230342 T1 HRP20230342 T1 HR P20230342T1 HR P20230342T T HRP20230342T T HR P20230342TT HR P20230342 T HRP20230342 T HR P20230342T HR P20230342 T1 HRP20230342 T1 HR P20230342T1
Authority
HR
Croatia
Prior art keywords
compound according
consist
branched alkyl
cationic lipid
carbon atoms
Prior art date
Application number
HRP20230342TT
Other languages
English (en)
Inventor
Joseph E. Payne
Padmanabh Chivukula
Original Assignee
Arcturus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/546,105 external-priority patent/US9593077B2/en
Priority claimed from US14/707,876 external-priority patent/US9365610B2/en
Application filed by Arcturus Therapeutics, Inc. filed Critical Arcturus Therapeutics, Inc.
Publication of HRP20230342T1 publication Critical patent/HRP20230342T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/10—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Claims (10)

1. Spoj, naznačen time, da je predstavljen formulom III: [image] u kojoj R1 se sastoji od razgranatog alkila s 12 do 20 ugljika, R2 se sastoji od razgranatog alkila s 12 do 20 ugljika, svaki od L1 i L2 se sastoji od veze ili ravnog alkila koji ima 1 do 3 atoma ugljika, X se sastoji od S ili O, L3 se sastoji od veze, R3 se bira od etilena, n-propilena ili izopropilena, i R4 i R5 su isti ili različiti, od kojih se svaki sastoji od ravnog ili razgranatog alkila koji se sastoji od 1 do 6 ugljika; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, naznačena time, da se X sastoji od S.
3. Spoj prema patentnom zahtjevu 1, naznačena time, da se L1 i L2 oba sastoje od ravnog alkila koji ima 1 do 3 atoma ugljika.
4. Spoj prema patentnom zahtjevu 1, naznačena time, da R3 je etilen.
5. Spoj prema patentnom zahtjevu 1, naznačena time, da R3 je n-propilen ili izopropilen.
6. Spoj prema patentnom zahtjevu 1, naznačena time, da se svaki od R4 i R5 sastoji od metila, etila ili izopropila.
7. Spoj prema patentnom zahtjevu 1, naznačena time, da se L1 i L2 oba sastoje od veze.
8. Spoj prema patentnom zahtjevu 1, naznačena time, da se L1 i L2 oba sastoje od metilena.
9. Spoj prema patentnom zahtjevu 1, naznačena time, da se R1 i R2 oba sastoje od razgranatog alkila od 19 ili 20 atoma ugljika.
10. Spoj prema patentnom zahtjevu 1, naznačena time, da se R1 i R2 oba sastoje od razgranatog alkila od 13 ili 14 atoma ugljika.
HRP20230342TT 2014-11-18 2015-05-11 Kationski lipid koji se može ionizirati za isporuku rna HRP20230342T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/546,105 US9593077B2 (en) 2013-11-18 2014-11-18 Ionizable cationic lipid for RNA delivery
US14/707,796 US9567296B2 (en) 2013-11-18 2015-05-08 Ionizable cationic lipid for RNA delivery
US14/707,876 US9365610B2 (en) 2013-11-18 2015-05-08 Asymmetric ionizable cationic lipid for RNA delivery
PCT/US2015/030218 WO2016081029A1 (en) 2014-11-18 2015-05-11 Ionizable cationic lipid for rna delivery
EP15724466.6A EP3221293B1 (en) 2014-11-18 2015-05-11 Ionizable cationic lipid for rna delivery

Publications (1)

Publication Number Publication Date
HRP20230342T1 true HRP20230342T1 (hr) 2023-06-09

Family

ID=56014367

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230342TT HRP20230342T1 (hr) 2014-11-18 2015-05-11 Kationski lipid koji se može ionizirati za isporuku rna

Country Status (20)

Country Link
EP (1) EP3221293B1 (hr)
JP (1) JP6637988B2 (hr)
KR (1) KR102380363B1 (hr)
CN (1) CN107207428A (hr)
AU (1) AU2015350561B2 (hr)
CA (1) CA2968060C (hr)
DK (1) DK3221293T3 (hr)
ES (1) ES2946110T3 (hr)
FI (1) FI3221293T3 (hr)
HK (1) HK1244479A1 (hr)
HR (1) HRP20230342T1 (hr)
HU (1) HUE062130T2 (hr)
IL (1) IL252291B (hr)
LT (1) LT3221293T (hr)
NZ (1) NZ732777A (hr)
PL (1) PL3221293T3 (hr)
PT (1) PT3221293T (hr)
RS (1) RS64078B1 (hr)
SI (1) SI3221293T1 (hr)
WO (1) WO2016081029A1 (hr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074085A1 (en) 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
US10975388B2 (en) 2016-12-14 2021-04-13 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) * 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US20200046830A1 (en) * 2017-03-30 2020-02-13 The Government Of The United States, As Represented By The Secretary Of The Army Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
WO2019191780A1 (en) * 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
CA3098262A1 (en) 2018-04-25 2019-10-31 Ethris Gmbh Cryoprotective agents for particulate formulations
KR20190127277A (ko) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
EP3805198B1 (en) * 2018-06-08 2023-09-20 FUJIFILM Corporation Compound, salt thereof and lipid particles
EP3891274B1 (en) 2018-12-06 2023-10-18 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
CN113840926A (zh) * 2019-03-19 2021-12-24 阿克丘勒斯治疗公司 脂质包封的rna纳米颗粒的制备方法
JP7241869B2 (ja) 2019-06-07 2023-03-17 富士フイルム株式会社 脂質組成物
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CA3158293A1 (en) 2019-11-15 2021-05-20 Fujifilm Corporation Lipid composition
CN115667530A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒dna载体和其用于表达因子ix治疗剂的用途
CA3172591A1 (en) 2020-03-24 2021-09-30 Douglas Anthony KERR Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
KR20230065281A (ko) 2020-09-13 2023-05-11 아크투루스 쎄라퓨틱스, 인크. 큰 rna의 지질 나노입자 캡슐화
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2022232286A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Lipid nanoparticles for nucleic acid delivery
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN114213295B (zh) * 2022-02-22 2022-05-20 中国科学院基础医学与肿瘤研究所(筹) 一种阳离子化合物、制备方法及其复合物和用途
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024064910A1 (en) 2022-09-23 2024-03-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
CN116270543B (zh) * 2023-05-19 2023-09-26 清华大学 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511069A (en) 1981-06-04 1985-04-16 The Pharmasol Corporation Dispensing system
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
PL169576B1 (pl) 1990-10-12 1996-08-30 Max Planck Gesellschaft Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
AU2011245987B2 (en) * 2010-04-28 2016-12-15 Kyowa Hakko Kirin Co., Ltd Cationic lipid
RU2769872C2 (ru) * 2011-06-08 2022-04-07 Нитто Денко Корпорейшн СОЕДИНЕНИЯ ДЛЯ НАЦЕЛЕННОЙ ДОСТАВКИ ЛЕКАРСТВЕННОГО СРЕДСТВА И УСИЛЕНИЯ АКТИВНОСТИ siPHK
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
AU2013270685B2 (en) * 2012-06-08 2017-11-30 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
WO2015074085A1 (en) * 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery

Also Published As

Publication number Publication date
CA2968060A1 (en) 2016-05-26
AU2015350561B2 (en) 2020-01-30
SI3221293T1 (sl) 2023-05-31
CA2968060C (en) 2023-06-20
WO2016081029A1 (en) 2016-05-26
IL252291A0 (en) 2017-07-31
HUE062130T2 (hu) 2023-09-28
JP2017535610A (ja) 2017-11-30
KR20170095241A (ko) 2017-08-22
RS64078B1 (sr) 2023-04-28
FI3221293T3 (fi) 2023-04-05
LT3221293T (lt) 2023-03-27
CN107207428A (zh) 2017-09-26
JP6637988B2 (ja) 2020-01-29
IL252291B (en) 2021-08-31
NZ732777A (en) 2023-06-30
EP3221293A1 (en) 2017-09-27
AU2015350561A1 (en) 2017-07-06
PL3221293T3 (pl) 2023-07-10
ES2946110T3 (es) 2023-07-12
HK1244479A1 (zh) 2018-08-10
KR102380363B1 (ko) 2022-03-29
PT3221293T (pt) 2023-03-16
EP3221293B1 (en) 2023-03-01
DK3221293T3 (da) 2023-04-03

Similar Documents

Publication Publication Date Title
HRP20230342T1 (hr) Kationski lipid koji se može ionizirati za isporuku rna
HRP20221536T1 (hr) Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
HRP20231742T1 (hr) Kationski lipid koji se može ionizirati za isporuku rna
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
FI4076662T3 (fi) Syöpää torjuvina aineina hyödyllisiä pyratsolyylijohdannaisia
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
PH12016501693A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
TN2018000106A1 (en) Farnesoid x receptor modulators
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
NZ720174A (en) Ionizable cationic lipid for rna delivery
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
PH12016500806A1 (en) Urea derivative or pharmacologically acceptable salt thereof
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
IL267899A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
MX348831B (es) Administración parenteral de tapentadol.
PH12015502632A1 (en) Cxcr7 receptor modulators
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
TN2016000061A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
IL252579B (en) History of methyl-(1h-pyrazolo-4-yl-)-3-methyl-1h-pyrazolo[3,4-d]pyrimidine and pharmaceutical preparations containing them
MX2017008983A (es) Composición farmaceútica de sulfonamida.
IL240136B (en) Pharmaceutical preparations containing n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a salt Pharmacists accept, solvate or its dissolved salt